Nordic Nanovector: Results From Preclinical Studies of Betalutin® in Combination with Rituximab in non-Hodgkin
Lymphoma Model to Be Presented at ASH
Nordic Nanovector ASA (OSE:NANO)(OSE:NANOO)announces that a poster describing the therapeutic effect of combined treatment with
Betalutin® (177Lu-satetraxetan-lilotomab) and rituximab in a preclinical model of non-Hodgkin lymphoma (NHL) (abstract 4189) will
be presented at the 58th Annual American Society of Hematology (ASH) meeting (3-6 December 2016 in San Diego, CA, USA). These
studies build on previously presented data showing that treatment with Betalutin® increased binding of rituximab to NHL cells and
uptake of rituximab in NHL tumours. The combination treatment resulted in 90-100 % survival for 150 days after treatment, while
each treatment alone gave from 10 to 40 % survival.
The ASH annual meeting is the premier event for scientific exchange in the field of hematology, attracting more than 20,000
attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000
abstracts are accepted for oral and poster presentations through an extensive peer review process.
Poster details
Abstract 4189
Abstract title: Combination of 177lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in
Preclinical Models of Non-Hodgkin Lymphoma
Authors: Repetto-Llamazares, AHV et al.
Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
Date/Time: Monday, 5 December 2016, 6:00 PM - 8:00 PM (PST)
Location: San Diego Convention Center, Hall GH
Link to abstract: https://ash.confex.com/ash/2016/webprogram/Paper89561.html
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in
haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin
Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing
market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low
intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2
study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major
types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core
markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC
pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
IR enquiries
Luigi Costa,
Chief Executive Officer
Cell: +41 79 124 8601
or
Tone Kvåle
Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
or
Media enquiries
Mark Swallow/David Dible
(Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector@citigatedr.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103006033/en/